{"product_id":"vcyt-ansoff-analysis","title":"(VCYT) Veracyte, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Expansion Decisions with the Full Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Veracyte, Inc. Ansoff Matrix Analysis lays out the company’s growth options across market penetration, market development, product development, and diversification in a concise, actionable grid—useful for strategy, investment, or planning. The page already displays a real preview of the analysis so you can judge style and substance before buying; purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAfirma thyroid nodule adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAfirma Genomic Sequencing Classifier and Xpression Atlas help rule out benign indeterminate thyroid nodules, cutting avoidable surgery and pulling more patients into the same thyroid care path. That is classic market penetration: more use in an existing clinical market, not a new one. Veracyte says Afirma has been used in more than 1.5 million patients, showing deep adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDecipher prostate testing depth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDecipher Prostate Biopsy and Radical Prostatectomy tests fit into existing urology and oncology workflows, so Veracyte, Inc. can win more share without changing how doctors diagnose prostate cancer. In 2026, U.S. prostate cancer cases are expected to top 313,000, giving the company a large current market to penetrate. More routine use of these tests can lift test volume and pull through repeat ordering. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProsigna breast assay uptake\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProsigna breast cancer assay already sits in an established breast oncology niche, so Veracyte can grow market penetration by increasing ordering in clinics that treat early-stage HR+\/HER2- disease. Breast cancer remains the most common cancer in women, with 2.3 million new cases in 2022, so even small share gains can scale. The main lever is broader guideline-led use and repeat adoption at current sites.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePercepta lung diagnostics expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVeracyte, Inc.'s Percepta Genomic Sequencing Classifier and Percepta Nasal Swab target lung cancer diagnosis, so wider use in current workups deepens market penetration inside respiratory oncology. Veracyte reported 2025 revenue growth in its lung portfolio, with Percepta positioned for earlier pre-biopsy and post-imaging use. That keeps the focus on the same patient pool, not a new market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame lung cancer workup market\u003c\/li\u003e\n\u003cli\u003eBroader use boosts test adoption\u003c\/li\u003e\n\u003cli\u003ePercepta supports earlier diagnosis\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEnvisia and Immunoscore utilization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEnvisia Genomic Classifier and Immunoscore Colon Cancer both sit in established, high-volume diagnostic paths, so Veracyte, Inc. can expand share by raising test use in the same physician and lab channels. Envisia supports interstitial lung disease workups, including idiopathic pulmonary fibrosis, while Immunoscore adds value in colon cancer care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame channels, lower adoption friction\u003c\/li\u003e\n\u003cli\u003eWorks in mature clinical categories\u003c\/li\u003e\n\u003cli\u003eShare gains come from deeper utilization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte Grows by Winning More Share in Existing Cancer Pathways\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte, Inc. grows market penetration by driving more use of Afirma, Decipher, and Prosigna in the same thyroid, prostate, and breast cancer pathways. Afirma has been used in more than 1.5 million patients, and U.S. prostate cancer cases are projected to exceed 313,000 in 2026, so share gains come from deeper adoption, not new markets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eTest\u003c\/th\u003e\n\u003cth\u003e2026\/2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAfirma\u003c\/td\u003e\n\u003ctd\u003e1.5M+ patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDecipher\u003c\/td\u003e\n\u003ctd\u003e313K+ U.S. cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProsigna\u003c\/td\u003e\n\u003ctd\u003e2.3M breast cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003ePercepta, Envisia, and Immunoscore also fit existing care routes, so higher order volume can lift Veracyte, Inc. revenue without changing the core customer base.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes Veracyte, Inc.’s growth strategy through the four core directions of the Ansoff Matrix\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a quick Veracyte, Inc. Ansoff Matrix view to relieve growth-planning uncertainty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAggregates primary, third‑party, and company sources to substantiate Veracyte’s market, product, and expansion assumptions for Ansoff Matrix analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal test commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte, Inc. uses market development when it sells the same genomic tests in new countries and regions, rather than changing the product. As a global diagnostics company, it can extend existing assays into more clinical markets and payer systems, which lifts revenue without new test design. This fits Ansoff’s market development because the market expands while the core test stays the same.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThyroid testing geography expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAfirma and Xpression Atlas can move into new geographies where thyroid nodule workups are growing, because the clinical need is already proven and the buyer shifts from U.S. accounts to local labs, hospitals, and payers. Thyroid nodules are common, with ultrasound detecting them in up to 60% of adults, so the addressable base is broad.\u003c\/p\u003e\n\u003cp\u003eThis is pure market development: the same tests, new countries, new reimbursement paths, and new referral networks. Veracyte, Inc. can scale faster here than with a new product launch, but success depends on local validation, regulatory clearance, and physician adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLung diagnostics geography expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte, Inc. can expand Percepta and Envisia into more lung-care markets without changing the tests, because both already support real clinical decisions. The move is geographic reach, not product redesign, and it fits a market development play. That gives Veracyte a way to grow adoption where bronchoscopy and interstitial lung disease workups are already standard practice.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner channel expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVeracyte’s partner channel expansion can widen reach without building every sales route itself. Its technology licensing and collaboration links with Johnson \u0026amp; Johnson, Acerta Pharma, and CareDx can open new clinician and lab networks for the existing menu of tests.\u003c\/p\u003e\n\u003cp\u003eThis matters because channel partners already serve large oncology and transplant testing workflows, so Veracyte can plug into active demand faster. In fiscal 2025, Veracyte reported 1.4 million+ tests performed, showing a broad base that partners can help extend into new accounts.\u003c\/p\u003e\n\u003cp\u003eThe upside in Ansoff terms is market development: sell current products through new channels and geographies. If partner-led access lifts conversion even a little, the revenue effect can scale quickly on Veracyte’s recurring test volume.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartners broaden customer access\u003c\/li\u003e\n\u003cli\u003eLicensing lowers go-to-market cost\u003c\/li\u003e\n\u003cli\u003eExisting tests can scale faster\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNew specialist adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVeracyte, Inc. spans six disease areas, thyroid, prostate, breast, lung, interstitial lung disease, and colon cancer, so the same tests can reach more specialists and care settings. That breadth supports market development by moving into new clinics without building a new product from scratch.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSix disease areas widen specialist reach.\u003c\/li\u003e\n\u003cli\u003eSame tests fit new clinical channels.\u003c\/li\u003e\n\u003cli\u003eMore settings can lift test volume.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor a 2025-2026 lens, that model matters because Veracyte, Inc. can sell one portfolio into multiple referral paths, which lowers channel risk and speeds adoption. The key play is not new tests first, but broader use of existing ones.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte Expands by Taking Proven Tests to New Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte, Inc.’s market development play is selling the same genomic tests into new geographies, payer systems, and referral channels. In fiscal 2025, it performed 1.4 million+ tests across six disease areas, showing a base that can scale beyond the U.S. without changing the core product.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFiscal 2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTests performed\u003c\/td\u003e\n\u003ctd\u003e1.4 million+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDisease areas\u003c\/td\u003e\n\u003ctd\u003e6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrategy\u003c\/td\u003e\n\u003ctd\u003eNew markets, same tests\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eVeracyte, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePercepta Genomic Atlas\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePercepta Genomic Atlas fits Veracyte, Inc.'s product development move in Ansoff Matrix: a new test for an existing lung cancer market. It expands the Percepta lung franchise into treatment decisions, where lung cancer still causes about 1.8 million deaths a year worldwide. This is a high-value, high-fit launch, but uptake will depend on clinical proof and reimbursement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnvisia nCounter version\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte is refining Envisia Classifier into an nCounter-based assay for interstitial lung disease, including idiopathic pulmonary fibrosis, so this is product development, not a new market play. The shift to a new assay format keeps the same clinical need but changes the technology used to deliver results, which can help standardize testing and support broader lab use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLymphMark lymphoma subtyping\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLymphMark lymphoma subtyping is a future diagnostic test that would add a new oncology product to Veracyte, Inc.'s menu. That fits product development in the Ansoff Matrix, because Veracyte is using its existing commercial platform to launch a new test for the same healthcare market. In the U.S., lymphoma affects about 90,000 people each year, so precise subtyping can support better treatment choices and payer value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePercepta decision support upgrade\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePercepta Genomic Atlas extends Veracyte, Inc.'s lung diagnostics line with treatment-decision support, so it is a product development move in Ansoff: a new product for an existing lung-cancer customer base. That fits the same market and can deepen use after diagnosis, when lung cancer still drives about 2.5 million new cases and 1.8 million deaths a year worldwide.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew product, same lung market\u003c\/li\u003e\n\u003cli\u003eAdds treatment-choice support\u003c\/li\u003e\n\u003cli\u003eBuilds on Percepta franchise\u003c\/li\u003e\n\u003cli\u003eTargets existing customers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eXpression Atlas expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXpression Atlas expands Veracyte, Inc.’s thyroid menu by adding genomic detail to Afirma’s nodule workup, so it is product development in the same market. Veracyte reported FY2024 revenue of $378.4 million, showing the thyroid franchise sits inside a scaled diagnostics base. More menu depth can lift use per case and support more follow-on testing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eXpression Atlas deepens thyroid testing.\u003c\/li\u003e\n\u003cli\u003eFits existing Afirma users and cases.\u003c\/li\u003e\n\u003cli\u003eRaises value per thyroid nodule workup.\u003c\/li\u003e\n\u003cli\u003eUses product development, not new markets.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte Expands Test Depth, Not Market Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte, Inc.'s product development move is clear: it adds new tests to existing lung, thyroid, and blood-cancer channels, not new markets. Percepta Genomic Atlas, Envisia on nCounter, LymphMark, and Xpression Atlas can lift value per case in a $378.4 million FY2024 base, but adoption still hinges on clinical proof and payer coverage.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eTest\u003c\/th\u003e\n\u003cth\u003eFit\u003c\/th\u003e\n\u003cth\u003eUse\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePercepta Genomic Atlas\u003c\/td\u003e\n\u003ctd\u003eLung\u003c\/td\u003e\n\u003ctd\u003eTreatment choice\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnvisia nCounter\u003c\/td\u003e\n\u003ctd\u003eILD\u003c\/td\u003e\n\u003ctd\u003eSame need, new format\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLymphMark\u003c\/td\u003e\n\u003ctd\u003eLymphoma\u003c\/td\u003e\n\u003ctd\u003eSubtyping\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eXpression Atlas\u003c\/td\u003e\n\u003ctd\u003eThyroid\u003c\/td\u003e\n\u003ctd\u003eDeeper workup\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLymphoma market entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLymphMark gives Veracyte a new lymphoma subtyping product, so this is diversification: a new product in a new oncology submarket. Lymphoma adds to Veracyte's core menu in thyroid, lung, breast, prostate, and colon cancer, widening reach beyond its current molecular testing base. The U.S. still sees roughly 90,000 new lymphoma cases a year, so the market is real, not niche.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLung treatment decision market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePercepta Genomic Atlas pushes Veracyte beyond diagnosis into lung cancer treatment decisions, so it fits Ansoff’s product development and market development mix. Lung cancer still drives about 2.4 million new cases and 1.8 million deaths a year worldwide, which shows the size of the decision market. A new genomic product for a new clinical use case can widen adoption and add revenue beyond initial testing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003enCounter platform expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte, Inc.’s Envisia Classifier on the nCounter platform shifts the assay workflow, so it targets a new lab buying decision and can lift adoption beyond the original platform base. That is diversification in Ansoff terms: the same diagnostic moves into a new product-market mix. Veracyte reported 2024 revenue of $389.4 million, showing the scale to push platform-based expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eJohnson \u0026amp; Johnson licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVeracyte’s technology licensing tie-up with Johnson \u0026amp; Johnson supports diversification in the Ansoff Matrix by opening new diagnostic development paths beyond its core test portfolio. Partner structures like this can speed access to IP, clinical know-how, and new use cases without building every asset in-house. That helps Veracyte broaden revenue potential while keeping platform risk lower.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpands beyond standalone tests\u003c\/li\u003e\n\u003cli\u003eUses external IP to speed development\u003c\/li\u003e\n\u003cli\u003eSupports adjacent market entry\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAcerta Pharma and CareDx collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVeracyte, Inc.'s deals with Acerta Pharma and CareDx add 2 partner-led development paths, so the company is not just selling core tests but also reaching new market routes. That fits Ansoff diversification: new products plus new channels, which can spread risk and widen the addressable base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2 collaboration partners\u003c\/li\u003e\n\u003cli\u003eNew routes to market\u003c\/li\u003e\n\u003cli\u003ePartner-led development\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte Expands Beyond Core Diagnostics With New Oncology Growth Paths\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte’s diversification is clear in LymphMark, which enters lymphoma subtyping, a new oncology niche beyond its core test base. Percepta Genomic Atlas also widens the mix by moving into lung cancer treatment decisions, while Johnson \u0026amp; Johnson and CareDx deals add partner-led paths into new markets. Together, these moves broaden revenue options beyond core diagnostics.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$389.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLymphoma cases US\u003c\/td\u003e\n\u003ctd\u003e~90,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLung cancer cases global\u003c\/td\u003e\n\u003ctd\u003e~2.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235217973513,"sku":"vcyt-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/vcyt-ansoff-matrix.webp?v=1785735165","url":"https:\/\/dcfanalyst.com\/products\/vcyt-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}